Skip to main content
    N

    Neuropace Inc (NPCE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $7.97
    +0.41 (+5.42%)

    Market Cap: $260.45M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Neuropace Inc (NPCE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Neuropace reported revenue of $99.99M for the fiscal year ended Dec 31, 2025, up 25.1% from the year before. That year, net income was -$21.46M with a net margin of -21.5%, operating cash flow was -$11.01M and free cash flow was -$11.34M. The quarter ended Sep 30, 2026 had revenue of $23.10M and net income of -$3.30M.

    Revenue and Margins

    The operating margin was -16.3% in the fiscal year ended Dec 2025, the highest of the 7 years shown. Over the 6 years to Dec 2025, revenue grew from $36.97M, a compound annual rate of 18.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$99.99M+25.1%77.2%-16.3%-21.5%
    Dec 2024$79.91M+22.1%73.9%-27.1%-34.0%
    Dec 2023$65.42M+43.7%73.6%-41.5%-50.4%
    Dec 2022$45.52M+0.7%71.4%-89.6%-103.4%
    Dec 2021$45.18M+9.8%74.0%-52.5%-79.9%
    Dec 2020$41.14M+11.3%73.6%-31.7%-59.0%
    Dec 2019$36.97MN/A71.6%-59.6%-81.1%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$99.99M$79.91M$65.42M$45.52M$45.18M$41.14M$36.97M
    Cost of revenue$22.77M$20.82M$17.30M$13.03M$11.75M$10.87M$10.51M
    Gross profit$77.22M$59.09M$48.12M$32.49M$33.44M$30.27M$26.46M
    Research and development$27.89M$23.65M$20.78M$21.95M$18.21M$15.70M$18.29M
    Operating income-$16.34M-$21.67M-$27.17M-$40.79M-$23.74M-$13.05M-$22.03M
    Net income-$21.46M-$27.14M-$32.96M-$47.08M-$36.08M-$24.28M-$29.97M
    EBITDA-$14.64M-$19.37M-$25.60M-$37.89MN/A-$9.03M-$20.07M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$23.10M$22.83M$22.07M$26.59M$23.35M$19.50M$22.52M$21.47M$21.06M$19.26M$18.12M$18.01M
    Gross profit$19.47M$18.91M$18.05M$20.58M$19.17M$16.21M$17.34M$16.19M$15.42M$14.13M$13.34M$13.54M
    Operating income-$2.08M-$5.14M-$5.57M-$1.77M-$4.03M-$8.19M-$5.15M-$3.65M-$4.24M-$6.23M-$7.54M-$5.05M
    Net income-$3.30M-$6.20M-$6.69M-$2.73M-$3.50M-$8.65M-$6.59M-$5.25M-$5.45M-$7.51M-$8.93M-$6.20M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $61.00M exceeded cash and equivalents by $39.31M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$105.56M$94.65M$107.65M$114.11M$133.56M$55.95M$21.09M
    Current assets$94.07M$81.34M$92.72M$97.71M$132.82M$54.56M$20.26M
    Cash and equivalents$21.69M$13.43M$18.06M$6.61M$19.19M$26.39M$4.12M
    Total liabilities$86.53M$86.63M$87.00M$79.33M$60.06M$62.36M$150.44M
    Short-term debt$2.12M$1.86M$1.63M$1.42MN/A$2.04M$62.80M
    Long-term debt$58.88M$59.52M$56.95M$52.91M$49.85M$50.82MN/A
    Shareholder equity$19.03M$8.01M$20.65M$34.78M$73.50M-$147.83M-$129.35M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$94.78M$96.99M$98.90M$105.56M$107.25M$106.11M$110.20M$94.65M$96.30M$94.39M$98.85M$107.65M
    Total liabilities$83.28M$85.11M$84.44M$86.53M$88.74M$86.68M$85.94M$86.63M$86.48M$84.50M$84.51M$87.00M
    Cash and equivalents$10.23M$12.54M$14.78M$21.69M$20.65M$22.86M$27.02M$13.43M$15.42M$12.84M$13.00M$18.06M
    Shareholder equity$11.49M$11.88M$14.45M$19.03M$18.52M$19.44M$24.27M$8.01M$9.82M$9.88M$14.34M$20.65M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$11.01M-$17.95M-$19.70M-$36.87M-$24.58M-$21.61M-$25.03M
    Capital expenditures$332.00K$306.00K$173.00K$603.00K$384.00K$62.00K$468.00K
    Free cash flow-$11.34M-$18.25M-$19.87M-$37.47M-$24.96M-$21.67M-$25.49M
    Share repurchases$49.55M$0$305.00K$347.00K$3.39M$210.00KN/A
    Investing cash flow-$332.00K$8.99M$23.03M$23.80M-$85.40M-$10.77M$3.62M
    Financing cash flow$19.60M$4.33M$8.13M$490.00K$102.53M$55.01M$21.37M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.76M-$3.90M-$5.90M$506.00K-$1.94M-$2.09M-$7.48M-$4.80M-$1.72M-$3.90M-$7.53M-$3.34M
    Capital expenditures$16.00K$125.00K$117.00K$97.00K$30.00K$168.00K$37.00K$39.00K$100.00K$63.00K$104.00K$32.00K
    Free cash flow-$2.78M-$4.03M-$6.02M$409.00K-$1.97M-$2.25M-$7.52M-$4.84M-$1.82M-$3.96M-$7.63M-$3.37M
    Last 12 quarters

    Frequently Asked Questions About NPCE

    What is Neuropace's annual revenue?

    Neuropace reported revenue of $99.99M for the fiscal year ended Dec 31, 2025.

    How fast is Neuropace's revenue growing?

    Revenue was up 25.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 30.0%.

    Is Neuropace profitable?

    No. Neuropace reported net income of -$21.46M for the fiscal year ended Dec 31, 2025, with a net margin of -21.5%.

    How much free cash flow does NPCE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$11.01M minus capital expenditures of $332.00K produced free cash flow of -$11.34M.

    How much debt does Neuropace have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $58.88M, short-term debt of $2.12M and cash and equivalents of $21.69M.